首页> 外文OA文献 >Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

【2h】

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

机译：雌激素剥夺的临床前和临床研究支持PDGF / Abl途径作为克服乳腺癌内分泌抵抗的新型治疗靶点

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Marion T Weigel; Zara Ghazoui; Anita Dunbier; Sunil Pancholi; Mitch Dowsett; Lesley-Ann Martin;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer [J] . Marion T Weigel, Zara Ghazoui, Anita Dunbier, Breast Cancer Research . 2012,第3期

机译：雌激素剥夺的临床前和临床研究支持PDGF / ABL途径作为克服乳腺癌内分泌抗性的新治疗靶标
2. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase [J] . Xiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, Breast Cancer Research . 2014,第5期

机译：通过Co-靶向哺乳动物靶标，蛋白激酶B或丝裂原蛋白激酶激酶激酶的哺乳动物靶标降低了雌激素受体阳性乳腺癌中PTEN水平的内分泌抵抗力
3. Overcoming resistance: targeting the PI3K/mTOR pathway in endocrine refractory breast cancer. [J] . Butt AJ Cancer biology & therapy . 2011,第11期

机译：克服耐药性：靶向内分泌难治性乳腺癌的PI3K / mTOR途径。
4. Quantitative Pathway Analysis of Basal Breast Cancer Cell Line Proteomes Reveals Signaling Features, Potential Therapeutic Targets [C] . Atim A. Enyenihi, Therese Hemstrom, Roman A. Zubarev American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：基础乳腺癌细胞系蛋白质组的定量途径分析显示信号传导特征，潜在的治疗目标
5. Overcoming Anti-Estrogen Resistance in Estrogen Receptor (ER)-Positive Breast Cancer: Rational Targeting of Phosphatidylinositol 3-Kinase (PI3K) and the Resurrection of Estrogen Therapy [D] . Hosford, Sarah 2018

机译：克服雌激素受体（ER）阳性乳腺癌中的抗雌激素抵抗：磷脂酰肌醇3-激酶（PI3K）的合理靶向和雌激素疗法的复活
6. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer [O] . Marion T Weigel, Zara Ghazoui, Anita Dunbier, 2012

机译：雌激素剥夺的临床前和临床研究支持PDGF / Abl途径作为克服乳腺癌内分泌抵抗的新型治疗靶点
7. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase [O] . 2014

机译：通过共同靶向哺乳动物雷帕霉素，蛋白激酶B或有丝分裂原激活的蛋白激酶激酶，克服雌激素受体阳性乳腺癌中PTEN降低引起的内分泌抵抗
8. Targeted Approaches to Overcoming Endocrine Resistance in Breast Cancer. [R] . Bergamaschi, A. 2012

机译：有针对性地克服乳腺癌内分泌抵抗的方法。

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅